FUSION I Assesses Safety and Tolerability of Two Doses of NATRECOR (Nesiritide) Administered to Patients With Worsening Congestive (Decompensated) Heart Failure Who Are Concurrently Receiving Their Usual Cardiac Medications and Are at High Risk for Hospitalization.
PHASE3CompletedINTERVENTIONAL
Enrollment
214
Participants
Timeline
Start Date
December 31, 2001
Study Completion Date
January 31, 2003
Conditions
Heart Failure, Congestive
Interventions
DRUG
nesiritide
DRUG
usual long term cardiac medications
DRUG
nesiritide
All Listed Sponsors
lead
Scios, Inc.
INDUSTRY
NCT00270361 - FUSION I Assesses Safety and Tolerability of Two Doses of NATRECOR (Nesiritide) Administered to Patients With Worsening Congestive (Decompensated) Heart Failure Who Are Concurrently Receiving Their Usual Cardiac Medications and Are at High Risk for Hospitalization. | Biotech Hunter | Biotech Hunter